While Valneva has just announced that the British government has ordered 40 million doses of its candidate vaccine against Covid-19 for 2022, another Nantes biotech is in the spotlight. Xenothera let know, Monday 1is February, that Xav-19, its anti-Covid-19 treatment, has a blocking effect “against the various variants currently circulating, known as British, South African, Brazilian, Danish and Scottish.” Xav-19 is currently in clinical trial in France and received the “national research priority” label in December. To date, around twenty hospitals offer volunteer patients to participate in the Xav-19 trial, led by the Nantes University Hospital.
–
– .
